Atibuclimab

Phase 2Monoclonal antibody

IImplicit Bioscience

Atibuclimab is one of 77 biologic programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Knee Osteoarthritis (knee OA)Not yet recruiting

Pilot StudyRecruiting

Acute Respiratory Distress SyndromeRecruiting

Heart FailurePhase 2

Active, not recruiting

Knee Osteoarthritis (knee OA)Phase 1

Not yet recruiting

Pilot StudyPhase 2

Recruiting

Acute Respiratory Distress SyndromePhase 2

Recruiting

Competition

Competitive Landscape

198 competitors in Heart Failure

#DrugCompanyPhaseTrials

Atibuclimab

IImplicit Bioscience

Phase 2

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Zemplar

Adriamycin

Activase

Xylocaine

1 9

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Knee Osteoarthritis (knee OA)

NCT07481474

Q2 2029

Phase 2Recruiting

Acute Respiratory Distress Syndrome

NCT06513949

Clinical

Trials by Indication[1]

Pilot Study1 trial

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Recruiting·IImplicit Bioscience·Phase 1/2·NCT06678074·10 enrolled

Heart Failure1 trial

IC14 for Treatment of Acute Decompensated Heart Failure

Active, not recruiting·IImplicit Bioscience·Phase 1/2·NCT06556810·10 enrolled

Acute Respiratory Distress Syndrome1 trial

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome

Recruiting·IImplicit Bioscience·Phase 2·NCT06513949·56 enrolled

Knee Osteoarthritis (Knee OA)1 trial

Pilot and Feasibility Study of Intra-articular Anti-CD14 for the Treatment of Knee Osteoarthritis

Not yet recruiting·VVA Office of Research and Development·Phase 1·NCT07481474·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Atibuclimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atibuclimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atibuclimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Implicit Bioscience company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: IImplicit Bioscience

Atibuclimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2029

Trials by Indication[1]

Pilot Study1 trial

Heart Failure1 trial

Acute Respiratory Distress Syndrome1 trial

Knee Osteoarthritis (Knee OA)1 trial

References

Drug Info

Quick Facts

Related News